AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

In response to growing demand for personalized, patient-centric aesthetic solutions1,2, Allergan Aesthetics, an AbbVie Company, is proud to unveil the new AA Signature program, an innovative approach ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery pl ...

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.

head of U.S. Immunology at UCB, said in the press release. The new single-injection dosage was approved on Oct. 14, 2024, based on studies that evaluated the bioequivalence of the drug’s 320 mg ...

Patients with atopic dermatitis (AD) who were prescribed dupilumab had a decreased risk for psychiatric and sleep disorders compared with those using conventional drugs, according to study findings ...

The immunology portfolio generated almost 50% ... As indicated in the very first table of my analysis, neuroscience and aesthetics are also important contributors to the company's consolidated ...

The TikTok aesthetics industrial complex never sleeps. Monoculture is dead, but the bright side to this is that now, more than ever, you can find niche styles that cater to your specific tastes ...